Your browser doesn't support javascript.
Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic.
Khiali, Sajad; Khani, Elnaz; B Rouy, Samineh; Entezari-Maleki, Taher.
  • Khiali S; Department of clinical pharmacy, Faculty of pharmacy, Tabriz University of Medical Sciences, Tabriz, 5166414766, Iran.
  • Khani E; Department of clinical pharmacy, Faculty of pharmacy, Tabriz University of Medical Sciences, Tabriz, 5166414766, Iran.
  • B Rouy S; Department of clinical pharmacy, Faculty of pharmacy, Tabriz University of Medical Sciences, Tabriz, 5166414766, Iran.
  • Entezari-Maleki T; Department of clinical pharmacy, Faculty of pharmacy, Tabriz University of Medical Sciences, Tabriz, 5166414766, Iran.
Future Microbiol ; 17: 377-391, 2022 03.
Article in English | MEDLINE | ID: covidwho-1704946
ABSTRACT
Despite the progress in the management of COVID-19, effective oral antiviral agents are still lacking. In the present review, the potential beneficial effects of molnupiravir in the management of COVID-19 are discussed. A literature search in Google Scholar, Scopus, PubMed and clinicaltrials.gov for the relevant articles regarding the pharmacokinetics, pharmacodynamics and clinical trials of molnupiravir in the management of COVID-19 is conducted. Most of the preclinical studies and available clinical trials showed a favorable short-term safety profile of molnupiravir; however, given its possible genotoxic effects, further trials are required to confirm the long-term efficacy and safety of molnupiravir in patients with COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / COVID-19 Drug Treatment Type of study: Prognostic study / Reviews Limits: Humans Language: English Journal: Future Microbiol Journal subject: Microbiology Year: 2022 Document Type: Article Affiliation country: Fmb-2021-0252

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / COVID-19 Drug Treatment Type of study: Prognostic study / Reviews Limits: Humans Language: English Journal: Future Microbiol Journal subject: Microbiology Year: 2022 Document Type: Article Affiliation country: Fmb-2021-0252